Jean Monnet University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Saint-Etienne France (1969)

Organization Overview

First Clinical Trial
2003
NCT00966290
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

5. University Jean Monnet, St Etienne, Laboratory SNA-EPIS EA 4607, France | Saint-Etienne (FR), University College Hospital | University Hospital of Saint-Etienne | University Hospital of Saint-Etienne, France | University Hospital of St Etienne | University Hospital Saint-Etienne

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Blood Coagulation Disorders (Phase 4)

Communicable Diseases (Phase 3)

Embolism (Phase 4)

Epilepsy (Phase 3)

Hemostatic Disorders (Phase 4)

Infections (Phase 3)

Pulmonary Embolism (Phase 4)

Retinal Neoplasms (Phase 2)

Retinoblastoma (Phase 2)

Seizures (Phase 3)

Thromboembolism (Phase 4)

Thrombosis (Phase 4)

Venous Thromboembolism (Phase 4)

Venous Thrombosis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 12